NWRN.SW Newron (SIX): pre-market CHF15.62 ahead of 24 Mar earnings, upside

NWRN.SW stock is trading pre-market at CHF15.62 as investors position ahead of Newron Pharmaceuticals S.p.A.’s earnings on 24 Mar 2026. The share is down 4.05% on the session from a previous close of CHF16.28, and technicals show an oversold reading that could amplify volatility around the report. We focus on the numbers investors will watch: revenue trends for Xadago, clinical updates on Evenamide and Ralfinamide, and guidance that could shift short-term price targets.

NWRN.SW stock snapshot and pre-market movers

Pre-market action shows price CHF15.62, open CHF17.10, day low CHF15.40 and day high CHF17.10 with volume at 69,775 versus an average of 149,199. Market cap stands at CHF311,790,726 and shares outstanding are 19,960,994. The stock trades below its 50-day average (CHF20.78) but above the 200-day average (CHF14.31). Reported EPS is 1.23 with a trailing PE of 12.70, metrics investors cite when sizing positions into earnings.

Earnings timing and key line items to watch for NWRN.SW stock

Newron will report on 24 Mar 2026 and the market expects clarity on commercial revenue from Xadago and any updates on Evenamide and Ralfinamide trials. Watch for guidance on R&D spend and licensing commentary that can change revenue visibility. Given Newron’s clinical-stage profile, any mention of trial timelines or partnering interest could move the stock more than routine revenue beats. Management commentary on European and US uptake of Xadago will be important for short-term sentiment.

Fundamentals and valuation for NWRN.SW stock

Newron shows solid profitability ratios for a biotech: net income per share CHF1.27, return on equity 16.66%, and operating margin near 58.78%. Cash per share is CHF2.16 and current ratio is 1.51, indicating near-term liquidity coverage. Valuation metrics include a price-to-sales of 5.73 and pb ratio of 216.75 driven by low book value per share (CHF0.08). Investors should weigh a trailing PE around 13.54 against concentrated product revenue and pipeline risk.

Meyka AI grade and model forecast for NWRN.SW stock

Meyka AI rates NWRN.SW with a score out of 100: 76.26 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year target CHF23.38 and a quarterly target CHF25.56 versus the current CHF15.62, implying an upside of 49.71% to the one-year figure. Forecasts are model-based projections and not guarantees.

Technical setup and short-term trading signals for NWRN.SW stock

Momentum indicators show RSI 24.29 and Stochastic %K 12.58, marking an oversold short-term condition. Bollinger Bands lower band sits at CHF15.68, very close to current price and suggesting tight downside room if volatility spikes. MACD is negative (MACD -1.15, signal -1.01) and ATR is CHF1.08, pointing to elevated intraday swings that traders should respect around the earnings release.

Risks and sector context for NWRN.SW stock

As a biotech in the Healthcare sector on the SIX (Switzerland), Newron is sensitive to trial outcomes, regulatory updates and partner negotiations. The sector’s average PE is around 28.90, so Newron’s multiples reflect both growth and concentration risk. Key risks include reliance on Xadago revenue, pipeline clinical setbacks, and typical biotech liquidity swings. No dividend yield is offered, and debt metrics warrant attention despite cash per share cushions.

Final Thoughts

Earnings on 24 Mar 2026 are the immediate catalyst for NWRN.SW stock trading on the SIX (Switzerland). At CHF15.62 pre-market, the share price already reflects near-term selling pressure and an oversold technical profile. Our analysis blends fundamentals, technicals and Meyka AI’s models: the platform’s one-year forecast of CHF23.38 implies ~49.71% upside versus the current price. Traders should watch revenue detail for Xadago, clinical trial updates on Evenamide and Ralfinamide, and management guidance for partnering or licensing moves. Short-term traders must respect the ATR CHF1.08 and tight Bollinger support at CHF15.68; long-term investors focused on pipeline potential may see the Meyka grade B+ (BUY) as a data-driven starting point. Remember, forecasts are model-based projections and not guarantees, and earnings can produce rapid re-pricing in either direction. For more background, see Newron’s website and our Meyka stock page for ongoing updates Newron Pharmaceuticals and Meyka NWRN.SW page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.